ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn M, Arcila M, Arrieta O, Planchard D, de Marinis F, Dingemans A, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne P, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba I, Wolf J, Wu Y, Yang S, Yang J, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Annals Of Oncology 2022, 33: 466-487. PMID: 35176458, DOI: 10.1016/j.annonc.2022.02.003.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerESMO Clinical Practice GuidelinesManagement of EGFRClinical practice guidelinesExpert consensus statementClinical trial designSummary of evidenceEpidermal growth factor receptorGrowth factor receptorAdvanced diseaseMetastatic diseaseMedical oncologyConsensus statementMultidisciplinary panelPractice guidelinesConsensus recommendationsTrial designExpert panel discussionAvailable evidenceEuropean SocietyFactor receptorCancerExpert panelBiomarker analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply